Drug Discovery in Cancer Epigenetics

Preface
I. Introduction
1: Basic Epigenetic Mechanisms and Phenomena
2: Cancer Epigenetics
II. Methods and Tools for Epigenetic Drug Development
3: Drug Discovery Methods
4: Preclinical Cancer Models with the Potential to Predict Clinical Response
5: Discovery of Biomarkers for Drug Development
6: Networks and Consortia for Epigenetic Drug Discovery
III. Classes of Epigenetic Drugs
7: DNA Methyltransferase Inhibitors
8: Small Molecule Inhibitors of Histone Deacetylases and Acetyltransferases as Potential Therapeutics in Oncology
9: Targeting histone methylation. The development of selective methyltransferase and demethylase inhibitors
10: Bromodomains as Anti-Cancer Targets
11: Epigenetic Readers Interpreting the Lysine Methylome - Biological Roles and Drug Discovery
12: Non coding RNAs: Clinical and Therapeutic Applications
IV. Clinical Implications of Epigenetic Therapy
13: Clinical Applications of Epigenetic Drugs
14: Efficacy of Combined Epigenetic Therapies
15: Predicting and Monitoring Responses to Epigenetic Drugs
16: Episensitization: A New Word for A New Concept
17: The Emerging Potential for Epigenetic Therapeutics in Non-Cancer Disorders

Dr. Gerda Egger is an Associate Professor of Epigenetics at the Clinical Institute of Pathology, Medical University of Vienna. Dr. Paola Barbara Arimondo is the Director of the Unité de Service et de Recherche (USR n°3388) entitled "Epigenetic Targeting of Cancer -ETaC-" which brings together basic and applied research - a joint laboratory of the Institut de Recherche Pierre Fabre (IRPF) and the CNRS. She is extremely experienced in researching regulatory pharmaceuticals and cancer epigenetics.